X4 Pharmaceuticals, Inc.
XFOR
$4.02
$0.030.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.24M | -23.93M | -29.82M | -25.74M | 282.00K |
| Total Depreciation and Amortization | 223.00K | 223.00K | 223.00K | 355.00K | 476.00K |
| Total Amortization of Deferred Charges | 230.00K | 207.00K | 221.00K | 212.00K | 225.00K |
| Total Other Non-Cash Items | 2.60M | 2.45M | 2.16M | -519.00K | -10.07M |
| Change in Net Operating Assets | -2.41M | 5.52M | -606.00K | -4.21M | -3.28M |
| Cash from Operations | -19.60M | -15.53M | -27.82M | -29.90M | -12.37M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 19.25M | 16.85M | -28.67M | 23.11M | -3.14M |
| Cash from Investing | 19.25M | 16.85M | -28.67M | 23.11M | -3.14M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.00K | 146.09M | 86.91M | 5.63M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.00K | 146.09M | 86.91M | 5.63M | -- |
| Foreign Exchange rate Adjustments | -20.00K | 3.00K | -1.00K | 139.00K | 72.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -365.00K | 147.42M | 30.41M | -1.02M | -15.43M |